Gapping up
In reaction to strong earnings/guidance:
- N/A.
Select actively traded names showing strength:
- EA +1.7%, TSLA +1.6%, AMD +1.3%, AAPL +1.2%, NVDA +1%, NFLX +1%, FB +0.7%
Select Chinese related stocks trading higher:
- YNDX +2%, BABA +1.3%, BIDU +1.2%, MOMO +1.2%, WB +0.6%
Other news:
- MRNS +29.8% (announces top-line data from the Phase 2 open-label study in patients with CDKL5 disorder support advancing ganaxolone into a definitive late-stage clinical trial)
- CTRV +23.5% (announces that the FDA has approved an Investigational New Drug Application in the U.S. for its lead HBV compound, TXL for the treatment of chronic hepatitis B)
- IDRA+20.5% (presents positive Phase 1 data for Intratumoral IMO-2125 )
- RNN +13% (presents preliminary efficacy data from the Ongoing Phase IIa Clinical Trial of RX-3117 )
- TEVA +11.4% (present late-breaking present data presented highlighting primary and secondary outcome measure results from chronic and episodic migraine Phase III clinical trials; also appointed new CEO)
- RXDX +9.5% (confirms completion of enrollment of the efficacy data sets for both the NTRK tissue-agnostic cohort and the ROS1 NSCLC cohort to support dual NDA submissions in 2018)
- ARRY +7.5% (present Phase 3 COLUMBUS Part 2 results in BRAF-Mutant Melanoma)
- VKTX +4.3% (announces results from a gene expression analysis conducted as part of its recently completed study of VK2809),
- INO +3.8% (announces that an interim data analysis for its INO-5150)
- EXEL +2.2% (Exelixis and Ipsen report results from Phase 2 CABOSUN trial of Cabozantinib versus Sunitinib confirms primary endpoint analysis per investigator)
- INCY +2% (Incyte and Merck present progression-free survival data from ECHO-202 Trial )
- CBIO +2% (issued patents covering its coagulation Factor IX hemophilia product candidate from the State Intellectual Property Office (SIPO) in China)
- AZN +1.7% (presents results from a subgroup analysis of the SIROCCO and CALIMA Phase III trials)
- IONS +1.5% (presents new data from IONIS-STAT3-2.5Rx demonstrating antitumor activity in combination with Imfinzi)
Analyst comments:
- ATI +3.4% (upgraded to Buy from Underperform at BofA/Merrill )
- FEYE +2.8% (upgraded to Overweight from Equal-Weight at Stephens)
- MA +1.7% (upgraded to Buy from Neutral at Guggenheim)
- MU +1.1% (initiated with a Outperform at FBN Securities)
- TXT +0.9% (upgraded to Buy from Hold at Drexel Hamilton)